4VI.F GENOMTEC S.A. ZY -10
- Market cap
- EUR 9.27M
- P/E
- -
- P/B
- 2.66x
- ROE
- -54.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4VI.F undervalued?
Graham numberThe Graham number of GENOMTEC S.A. ZY -10 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GENOMTEC S.A. ZY -10 fundamental analysis
No fundamental analysis for GENOMTEC S.A. ZY -10 yet.
GENOMTEC S.A. ZY -10 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GENOMTEC S.A. ZY -10
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that enables the detection of pathogens, such as viruses, bacteria, and fungi, as well as genetic mutations through the analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addit…
Full company profileGENOMTEC S.A. ZY -10 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GENOMTEC S.A. ZY -10 annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 219K | 40.0K | 1.00K | 1.00K | 21.0K | 54.0K |
| Gross Profit | 128K | -3.23M | -793K | -4.31M | -7.96M | -8.14M |
| Operating Income | -10.2M | -11.3M | -9.11M | -11.1M | -10.2M | -8.33M |
| EBITDA | - | -11.2M | -7.76M | -8.73M | -7.39M | -5.58M |
| Net Income | -7.12M | -11.9M | -9.01M | -11.2M | -10.4M | -8.53M |
| EPS | -0.87 | -1.27 | -0.74 | -0.84 | -0.69 | -0.50 |
| Balance Sheet | ||||||
| Total Assets | 4.22M | 11.8M | 16.0M | 17.0M | 15.4M | 21.1M |
| Total Liabilities | 3.49M | 6.87M | 7.67M | 9.44M | 6.14M | 5.41M |
| Shareholders' Equity | 723K | 4.89M | 8.30M | 7.60M | 9.21M | 15.7M |
| Cash & Short-term Investments | 1.38M | 4.14M | 4.17M | 6.70M | 4.72M | 14.2M |
| Cash Flow | ||||||
| Operating Cash Flow | -5.50M | -3.60M | -7.95M | -6.72M | -11.2M | -1.13M |
| Capital Expenditure | 213K | 4.33M | 3.53M | 59.0K | 92.0K | 78.0K |
| Free Cash Flow | -5.71M | -7.93M | -11.5M | -6.78M | -11.3M | -1.21M |
| Ratios | ||||||
| ROE | -984.1% | -244.0% | -108.6% | -147.5% | -113.2% | -54.5% |
| ROA | -168.8% | -101.5% | -56.4% | -65.8% | -67.9% | -40.5% |
| Net Profit Margin | -3,248.9% | -29,820.0% | -901,300.0% | -1,120,800.0% | -49,671.4% | -15,803.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
GENOMTEC S.A. ZY -10 dividends
GENOMTEC S.A. ZY -10 has not paid dividends in the last 5 fiscal years.
Who owns GENOMTEC S.A. ZY -10
- Insiders 15.37%
- Institutions 2.93%
- Public & others 81.70%
- Shares outstanding 17.1M
- Free float 11.8M
GENOMTEC S.A. ZY -10 company profile
- Company name
- GENOMTEC S.A. ZY -10
- Ticker
- 4VI.F
- ISIN
- PLGNMTC00017
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 32
- Fiscal year end
- December
- Address
- Bierutowska Street 57-59, Wroclaw, Poland, 51-317
- Phone
- 48 793 440 931
- Website
- genomtec.com
About GENOMTEC S.A. ZY -10
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that enables the detection of pathogens, such as viruses, bacteria, and fungi, as well as genetic mutations through the analysis of biological material of patients using swabs, urine, and saliva. It also develops SNAAT chemistry for mutation detection in oncology. In addition, the company develops and commercializes tests used in the detection of viral infectious diseases and other areas. Genomtec S.A. was founded in 2016 and is based in Wroclaw, Poland.
GENOMTEC S.A. ZY -10 management
5- Mr. Miron Tokarski Ph.D.Co-Founder, CEO & Member of the Management Board
- Mr. Michal WachowskiCFO & Member of the Management Board
- Mr. Lee HuntleyCTO & Member of the Management Board
- Mr. Henryk Roguszczak M.Sc.Co-founder & Chief Designer
- Dr. Malgorzata Malodobra-MazurCo-founder and Director of Research & Development